Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and TheLeukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s... read more →
Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in... read more →
Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with... read more →
SutroVax Announces $85M Series C Financing led by TPG Growth
https://califesciences.org/california-life-sciences-association-elects-new-board-chair-adds-new-board-member/
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate,... read more →
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate... read more →
Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American... read more →
Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has... read more →
Will Rapidly Advance Promising Drug Candidates to the Clinic SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene... read more →